TCT 2019: IDEAL LM Inconclusive, While Onyx ONE Boosts Polymer-Based DES

Data from two late-breaking drug-eluting stent trials, presented on 26 September at Transcatheter Cardiovascular Therapeutics meeting in San Francisco, prompted mixed reactions from interventional cardiologists.

Skyscrapers in San Francisco at night - Image
The Transcatheter Cardiovascular Therapeutics conference is held in San Francisco from 24 September to 29 September • Source: shutterstock.com

Results of the IDEAL LM trial showed patients with left main coronary artery disease treated with Boston Scientific Corp.'s Synergy everolimus-eluting platinum-chromium stent with a biodegradable polymer fared equally well with short-duration dual antiplatelet therapy (DAPT) as patients treated with Abbott Laboratories Inc.'s Xience everolimus-eluting cobalt-chromium stent and a standard 12-month course of antiplatelet therapy.

Robert-Jan Van Geuns, from Erasmus Medical Center in Rotterdam, reported the results on 26 September at Transcatheter Cardiovascular Therapeutics meeting...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Clinical Trials

Digital Health Roundup: Digital Therapeutics Navigate GLP-1, Immersive Gaming; DHCoE AI Framework; Hello Heart

In this week’s Digital Health Roundup, Medtech Insight’s Ryan Nelson highlights Click Therapeutics’ FDA-cleared digital therapeutics (DTx) for depression and Sinaptica Therapeutics’ personalized neuromodulation for Alzheimer’s patients. Marion Webb discusses her interview with MindMaze’s John Krakauer on their gaming-focused DTx to help people recover from serious brain injuries. Elizabeth Orr introduces new voting members of the new Digital Health Advisory Committee and Natasha Barrow discusses Hello Heart’s new symptom-tracking feature in their heart-focused app.

MI-Business (Free-2): Prison Is the First Mental Health Visit for Many in Spain

 
• By 

Spain has one of the highest incarceration rates in Europe, with 160 individuals imprisoned per 100,000 residents. In 2020, 43,494 people were incarcerated in facilities not managed by regional health authorities — essentially all regions except Catalonia, the Basque Country, and Navarra.

TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

 

TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.

J&J MedTech Keeps Up Cardiovascular Momentum With Shockwave E8 Launch In US

Tim Schmid, executive VP and worldwide chairman of J&J MedTech, expects Shockwave, acquired in April, and Abiomed, purchased in late 2022, to be “long-term gems” for the company. Cardiovascular is among higher-growth segments where J&J has concentrated investments in recent years, along with robotic surgical systems.

More from R&D

Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

 

Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

Route 92 To Drive FreeClimb Neurointervention Sales With Extended Series F Funding

 

An additional $50m brings the neurovascular intervention specialist’s total Series F funding to $82m. Route 92 says it will use the capital to build its sales and support teams and pursue regulatory authorizations around the globe for its FreeClimb portfolio while advancing its SUMMIT MAX clinical trial for the investigational Monopoint Reperfusion System.

TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

 

TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.